{
    "clinical_study": {
        "@rank": "132949", 
        "acronym": "HSTCL", 
        "arm_group": {
            "arm_group_label": "Group 1", 
            "description": "To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and genetic mutations in patients who develop HSTCL."
        }, 
        "biospec_descr": {
            "textblock": "2 (3 to 5 mL) biomarker samples; separate consent 1 (4 mL) whole blood sample for DNA\n      isolation"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "To collect and store blood and biopsy samples obtained from CD or UC patients exposed to\n      adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and\n      genetic mutations in patients who develop HSTCL."
        }, 
        "brief_title": "Evaluation of Biomarkers and Genetic Mutations in Patients Exposed to Adalimumab With Crohn's Disease or Ulcerative Colitis Who Developed Hepatosplenic T-Cell Lymphoma", 
        "completion_date": {
            "#text": "September 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Crohn's Disease", 
            "Ulcerative Colitis", 
            "Hepatosplenic T-Cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Crohn Disease", 
                "Lymphoma", 
                "Ulcer", 
                "Lymphoma, T-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Non-Drug interventional study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female who has received a single dose of HUMIRA prior to a confirmed\n             diagnosis of HSTCL.\n\n          2. Confirmed diagnosis of CD or UC as documented by the AbbVie clinical or registry\n             investigator or patient's Health Care Provider (HCP).\n\n          3. Confirmed diagnosis of HSTCL by AbbVie review of the patient's medical history\n             including signs, symptoms, hematology and other laboratory data and pathology\n             reports.\n\n          4. Patients 18 years old and above must voluntarily sign and date each informed consent,\n             approved by an Independent Institutional Review Board (IRB), prior to the initiation\n             of any study-specific procedure.\n\n          5. For patients less than 18 years old, a parent or guardian must voluntarily sign and\n             date an informed consent approved by an Institutional Review Board (IRB).  Pediatric\n             patients will be included in all discussions in order to obtain verbal or written\n             assent according to applicable to IRB requirements.\n\n        Exclusion Criteria:\n\n          1. Male or female has not received adalimumab prior to a confirmed diagnosis of HSTCL.\n\n          2. Unconfirmed diagnosis of HSTCL, CD or UC, respectively.\n\n          3. The patient or the patient's HCP is unwilling to participate.\n\n          4. Patients, or parents or guardians in the case of patients less than 18 years of age,\n             who are unable and/or unwilling to sign informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population will include patients of any age with CD or UC in the US with HSTCL\n        who are identified through the sponsor's adverse event reporting systems and who were\n        exposed to HUMIRA prior to the diagnosis of HSTCL."
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087878", 
            "org_study_id": "F14-258"
        }, 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Hepatosplenic T-Cell Lymphoma", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "North Chicago", 
                    "country": "United States", 
                    "state": "Illinois"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicenter Study to Collect Samples for Future Evaluation of Biomarkers and Genetic Mutations in Patients Exposed to Adalimumab With Crohn's Disease (CD) or Ulcerative Colitis (UC) Who Developed Hepatosplenic T-Cell Lymphoma (HSTCL)", 
        "overall_contact": {
            "email": "sandra.m.fukumoto@abbvie.com", 
            "last_name": "Sandy   Fukumoto", 
            "phone": "+1 847-938-6826"
        }, 
        "overall_contact_backup": {
            "email": "erin.malloy@abbvie.com", 
            "last_name": "Erin E Malloy", 
            "phone": "+1 847-937-7307"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Majin  Castillo, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and genetic mutations in patients who develop HSTCL. A study to bank samples for future evaluation to identify genetic mutations and other biomarkers that predispose inflammatory bowel disease (IBD) patients to developing Hepatosplenic T-Cell Lymphoma (HSTCL).", 
            "measure": "Collection of Samples", 
            "safety_issue": "No", 
            "time_frame": "Upto 6 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087878"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}